157 related articles for article (PubMed ID: 37081302)
1. Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics.
Drescher SK; Jiao Y; Chen MJ; Kurumaddali A; Shao J; Amini E; Hochhaus G; Bulitta JB
Pharm Res; 2023 May; 40(5):1177-1191. PubMed ID: 37081302
[TBL] [Abstract][Full Text] [Related]
2. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
Hochhaus G; Chen MJ; Kurumaddali A; Schilling U; Jiao Y; Drescher SK; Amini E; Berger SM; Kandala B; Tabulov C; Shao J; Seay B; Abu-Hasan MN; Baumstein SM; Winner L; Shur J; Price R; Hindle M; Wei X; Carrasco C; Sandell D; Oguntimein O; Kinjo M; Delvadia R; Saluja B; Lee SL; Conti DS; Bulitta JB
AAPS J; 2021 Mar; 23(3):48. PubMed ID: 33768368
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
4. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate.
Allen A; Bareille PJ; Rousell VM
Clin Pharmacokinet; 2013 Jan; 52(1):37-42. PubMed ID: 23184737
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.
Minto C; Li B; Tattam B; Brown K; Seale JP; Donnelly R
Br J Clin Pharmacol; 2000 Aug; 50(2):116-24. PubMed ID: 10930963
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
Vutikullird AB; Gillespie M; Song S; Steinfeld J
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
[TBL] [Abstract][Full Text] [Related]
7. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.
Kirby S; Falcoz C; Daniel MJ; Milleri S; Squassante L; Ziviani L; Ventresca GP
Eur J Clin Pharmacol; 2001; 56(11):781-91. PubMed ID: 11294367
[TBL] [Abstract][Full Text] [Related]
8. Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling.
Krishnaswami S; Hochhaus G; Möllmann H; Barth J; Derendorf H
Int J Clin Pharmacol Ther; 2005 Mar; 43(3):117-22. PubMed ID: 15792395
[TBL] [Abstract][Full Text] [Related]
9. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.
Möllmann H; Wagner M; Krishnaswami S; Dimova H; Tang Y; Falcoz C; Daley-Yates PT; Krieg M; Stöckmann R; Barth J; Lawlor C; Möllmann AC; Derendorf H; Hochhaus G
J Clin Pharmacol; 2001 Dec; 41(12):1329-38. PubMed ID: 11762560
[TBL] [Abstract][Full Text] [Related]
10. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
Mehta R; Moore A; Riddell K; Joshi S; Chan R
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.
Kirjavainen M; Mattila L; Vahteristo M; Korhonen J; Lähelmä S
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):290-297. PubMed ID: 29493402
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers.
Soulele K; Macheras P; Silvestro L; Rizea Savu S; Karalis V
Eur J Pharm Sci; 2015 Dec; 80():33-42. PubMed ID: 26296862
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
[TBL] [Abstract][Full Text] [Related]
16. Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.
Bhagwat S; Schilling U; Chen MJ; Wei X; Delvadia R; Absar M; Saluja B; Hochhaus G
Pharm Res; 2017 Dec; 34(12):2541-2556. PubMed ID: 28799097
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
Nugent C; Yiu G; Song S; Caracta C
J Asthma; 2018 Aug; 55(8):898-906. PubMed ID: 28933971
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.
Weber B; Hochhaus G
AAPS J; 2015 Jul; 17(4):999-1010. PubMed ID: 25933600
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler.
Gillespie M; Song S; Steinfeld J
Allergy Asthma Proc; 2015; 36(5):365-71. PubMed ID: 26314817
[TBL] [Abstract][Full Text] [Related]
20. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids.
Kerwin EM; Gillespie M; Song S; Steinfeld J
J Asthma; 2017 Jan; 54(1):89-98. PubMed ID: 27285965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
